Endo K, Igarashi Y, Nisar M, Zhou Q H, Hakomori S
Biomembrane Institute, Seattle 98119.
Cancer Res. 1991 Mar 15;51(6):1613-8.
Sphingosine (SPN) has been claimed to be a negative modulator of transmembrane signaling through protein kinase C (PK-C) or some yet unidentified mechanism [for review see Y. A. Hannun and R. M. Bell, Science (Washington DC), 243: 500-507, 1989]. N,N-Dimethylsphingosine (DMS) was recently found to be a physiological cellular component and, in comparison to SPN, to show a stronger and stereospecific inhibitory effect on PK-C activity of A431 cells (for review see Y. Igarashi, Trends Glycosci. Glycotechnol., 2: 319-332, 1990; and S. Hakomori, J. Biol. Chem., 265: 18713-18716, 1990). (4E)-N,N,N-Trimethyl-D-erythro-sphingenine (TMS) is not detectable as a normal cellular component; however, it is expected to exhibit potent activity because of its quaternary ammonium ion structure, and in fact it showed much stronger inhibitory effect than DMS or SPN on PK-C activity (which plays an important role in cell growth regulation) in vitro. In view of these findings, we investigated the effects of SPN, DMS, and TMS on in vitro growth of various human carcinoma cell lines and on in vivo tumor growth in athymic nu/nu mice. Both DMS and TMS showed similar in vitro and in vivo growth inhibitory effects on tumor cells, despite the fact that TMS showed a much stronger inhibitory effect than DMS on PK-C activity of A431 cells. In contrast, SPN showed only a weak effect on in vitro cell growth and no effect on in vivo tumor growth. Tumor growth following s.c. inoculation of mice with human gastric carcinoma cell line MKN74 was inhibited in a dose-dependent manner by DMS, and tumor size was decreased after three or four consecutive daily injections of 0.5-mg doses of DMS or TMS. Increased tumor growth occurred after administration of these compounds was stopped; however, size of tumor remained significantly smaller than in groups treated with SPN or control saline. The effect of DMS or TMS on in vitro or in vivo MKN74 cell growth was stronger than that of 8-chloro-adenosine-cyclic 3':5'-monophosphate dihydrate, the most promising agent currently being used in clinical trials for inhibition of tumor growth by induction of differentiation. These results suggest that DMS or TMS could be useful anticancer agents through modification of transmembrane signaling related to cancer cell growth.
鞘氨醇(SPN)被认为是通过蛋白激酶C(PK-C)或某些尚未明确的机制对跨膜信号传导起负性调节作用的物质[综述见Y. A. 汉农和R. M. 贝尔,《科学》(华盛顿特区),243: 500 - 507,1989]。N, N - 二甲基鞘氨醇(DMS)最近被发现是一种生理性细胞成分,并且与SPN相比,对A431细胞的PK-C活性表现出更强且具有立体特异性的抑制作用(综述见Y. 五十岚,《糖科学与糖技术趋势》,2: 319 - 332,1990;以及S. 羽田野,《生物化学杂志》,265: 18713 - 18716,1990)。(4E)-N, N, N - 三甲基 - D - 赤型鞘氨醇(TMS)作为正常细胞成分无法检测到;然而,由于其季铵离子结构,预计它会表现出强大的活性,事实上它在体外对PK-C活性(在细胞生长调节中起重要作用)的抑制作用比DMS或SPN强得多。鉴于这些发现,我们研究了SPN、DMS和TMS对各种人癌细胞系体外生长以及对无胸腺裸鼠体内肿瘤生长的影响。尽管TMS对A431细胞的PK-C活性的抑制作用比DMS强得多,但DMS和TMS在体外和体内均对肿瘤细胞表现出相似的生长抑制作用。相比之下,SPN对体外细胞生长仅表现出微弱作用,对体内肿瘤生长则无作用。用人类胃癌细胞系MKN74皮下接种小鼠后,DMS以剂量依赖方式抑制肿瘤生长,连续每日注射0.5毫克剂量的DMS或TMS三或四次后肿瘤大小减小。停止给予这些化合物后肿瘤生长加快;然而,肿瘤大小仍显著小于用SPN或对照生理盐水处理的组。DMS或TMS对体外或体内MKN74细胞生长的作用比8 - 氯 - 腺苷 - 环3':5'-单磷酸二水合物更强,8 - 氯 - 腺苷 - 环3':5'-单磷酸二水合物是目前临床试验中用于通过诱导分化抑制肿瘤生长最有前景的药物。这些结果表明,DMS或TMS可能通过修饰与癌细胞生长相关的跨膜信号传导而成为有用的抗癌药物。